Overview

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Status:
Recruiting
Trial end date:
2022-08-17
Target enrollment:
Participant gender:
Summary
Primary Objective: - Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus Secondary Objectives: - Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus - To evaluate the efficacy of dupilumab in AD participants with chronic pruritus - To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals